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Abstract 1 
 2 
Deleted in Liver Cancer 2 (DLC2) is a novel RhoGTPase activating protein (RhoGAP) 3 
that regulates RhoA activity.  DLC2 is ubiquitously expressed in most tissues, 4 
including the brain, spinal cord and peripheral nerves, and is thought to be involved in 5 
actin cytoskeletal reorganization.  Unlike DLC1-deficient mice, DLC2-deficient 6 
mice (DLC2-/-) are viable and without gross anatomical abnormalities.  Interestingly, 7 
DLC2-/- mice exhibit hyperalgesia to noxious thermal stimuli and 8 
inflammation-inducing chemicals, such as formalin and acetic acid.  There was no 9 
difference in the structure or morphology of cutaneous or sural nerves between 10 
DLC2+/+ and DLC2-/- mice.  However, sensory nerve conduction velocity (SNCV) in 11 
DLC2-/- mice was significantly higher than that in DLC2+/+ mice, whereas motor 12 
nerve conduction velocity (MNCV) was not affected.  After formalin injection, 13 
DLC2-/- mice showed increased RhoA activity in spinal cord and an increased number 14 
of phosphorylated ERK1/2-positive cells.  The inflammatory hyperalgesia in DLC2-/- 15 
mice appeared to be mediated through the activation of RhoA and ERK1/2.  Taken 16 
together, DLC2 plays a key role in pain modulation during inflammation by 17 
suppressing the activation of RhoA and ERK to prevent an exaggerated pain response 18 
and that DLC2-/- mice provide a valuable tool for further understanding the regulation 19 
of inflammatory pain. 20 
21 
 3 
Introduction 1 
 2 
Deleted in Liver Cancer 2 (DLC2) is a member of the family of Deleted in Liver 3 
Cancer genes; it is also known as Steroidogenic Acute Regulatory protein 4 
(StAR)-related lipid transfer (START) Domain-containing protein 13 (DLC2).  This 5 
gene encodes a protein containing 1,113 amino acids that shares 51% identity and 6 
65% similarity with the amino acid sequence of DLC1 [1].  DLC2 has a sterile alpha 7 
(SAM) domain, a START domain and a Rho GTPase activating protein (RhoGAP) 8 
domain.  An additional functional domain was identified in residues 322-329 as an 9 
ATP/GTP-binding site [1].    10 
 11 
DLC2 was first thought to be a tumor suppressor gene because it is located on 12 
chromosome 13q12.3, a region often deleted in hepatocellular carcinoma (HCC) [2-9]. 13 
In addition, DLC2 expression is reduced in 18% of human HCC samples [1].  DLC2 14 
exhibited RhoGAP activity specific for RhoA, which may mediate stress fiber 15 
formation [1,10,11].  The increased expression of its RhoGAP domain inhibited the 16 
proliferation of breast cancer cells [10] and HepG2 cells [11] by inactivating RhoA.  17 
In addition, increased expression of its GAP domain inhibited the migration of HepG2 18 
cells [1,11].  However, one study showed that a DLC2 deficiency did not increase 19 
the rate of spontaneous liver tumor formation or diethylnitrosamine (DEN)-induced 20 
hepatocarcinogenesis [12].   21 
 22 
Activation of RhoA is involved in the initiation and maintenance of 23 
inflammatory and neuropathic pain [13,14].  Intraperitoneal injection of the ROCK 24 
inhibitor Y27632 in mice produced an anti-nociceptive effect to noxious thermal 25 
stimuli and inflammatory agents, such as formalin and acetic acid [14,15].  This was 26 
 4 
probably because RhoA and ROCK regulate glutamine and/or acetylcholine release 1 
from peripheral nerves [16-18].  Thus, RhoA/ ROCK plays a role in neurotransmitter 2 
release from sensory nerves.  RhoA is also critical for the regulation of actin 3 
cytoskeleton formation during many cellular events.  The regulation of the 4 
cytoskeleton, especially in nervous tissues, is important for neurite outgrowth, axonal 5 
targeting and branching.  Although DLC2 is thought to regulate RhoA, its role in 6 
actin cytoskeletal organization, the development of nervous tissues and neuropathic 7 
pain is not clear.  8 
 9 
In this study, we investigated nerve morphology in DLC2-/- mice and their response to 10 
noxious thermal stimuli and inflammatory chemicals.  We found that there was no 11 
significant difference in the structure of the cutaneous and sural nerves compared to 12 
that of DLC2+/+ mice under normal conditions.  In addition, hyperalgesia to heat and 13 
inflammation in DLC2-/- mice was associated with increased activity of RhoA and 14 
ERK1/2, the signaling molecules involved in hyperalgesia, in the dorsal horn of the 15 
spinal cord.   16 
 17 
Material and Methods 18 
 19 
Animals 20 
Male mice around 9 to 11 week-old were used.  Wild type (DLC2+/+) and 21 
DLC2-deficient (DLC2-/-) mice were used.  DLC2-/- mice were backcrossed to 22 
C57BL/6N for 6 generations.  For morphological assessment, DLC2+/+ and DLC2-/- 23 
mice (N7 backcross to C57BL/6N) were mated with Thy1-YFP mice, which had 24 
yellowish-green fluorescent protein in the sensory and motor neurons (31).  All mice 25 
were maintained in a 12/12 hr light/dark cycle with food and water ad libitum.  26 
 5 
Animal experiments were carried out following the guidelines set forth by the 1 
Committee on the Use of Live Animals in Teaching and Research at The University 2 
of Hong Kong.  3 
 4 
Reverse-transcription PCR (RT-PCR) 5 
For semi-quantitative RT-PCR analysis, total RNA was prepared from mouse 6 
tissues using TRI reagent.  First strand cDNA was synthesized from 1μg of total 7 
RNA using SuperScriptTM (Invitrogen) reverse transcriptase.  DLC2 mRNA and 8 
GAPDH were amplified by following primers: for DLC2 gene, a forward primer (5’- 9 
TGTGCTGGCAGGGACGGC) and a reverse primer (5’- 10 
TGCCAATGTGCTGTGACTTTGCAG) were used; for GAPDH, a forward primer 11 
(5’- CATCACCATCTTCCAGGA) and a reverse primer (5’- 12 
CAGATCCACGACGGACA) were used.  The annealing temperature of the PCR 13 
was 55  with 25 cycles.  After PCR, 10 µl of PCR reaction mixture was applied to 14 
electrophoresis.  The gel was stained and exposed to UV to visualize the band and 15 
captured by Gel Doc XR (Bio-Rad).  The intensity of the expected band was quantified 16 
by ImageJ (NIH).  The intensity of the bands in different lane was normalized with level 17 
of GAPDH, which served as a loading control. 18 
 19 
In situ hybridization 20 
A pair of specific primers for amplification of DLC2 riboprobe (forward primer: 21 
5’- GGTCTGCTCTATTCACA and reverse primer: 5’- 22 
TGCAAAGTCACAGCACATTGGCA) was designed using the free online software 23 
Primer 3 based on the published sequence of DLC2 (NM_146258.1).  PCR 24 
fragments of DLC2 were generated from mouse brain cDNA, and cloned into the 25 
pBluescript II SK+ vector.  One µg purified linearized DNA plasmid served as 26 
 6 
template for RNA probe synthesis by in vitro RNA transcription with DIG labeling.  1 
The antisense or sense RNA probes were synthesized with T7 or T3 RNA polymerase, 2 
respectively, in transcription buffer (400mM Tris-HCL pH8.0, 60mM MgCl2, 100mM 3 
Dithiothreitol, 20mM spermidine) and DIG RNA labeling mix (Genius).  The 4 
chromogenic reaction was carried out using BM purple in AP buffer. 5 
 6 
Hot plate test and tail flick test 7 
The animals were tested for their response to heat stimulus [19]. Mice were 8 
placed in the bottom of a 4 L glass beaker, which was incubated in a water-bath kept 9 
at 55oC, and the responsive time required for the mice to lick and lift their rear paws 10 
or jump was determined.  The maximum time for heat stimulus was 30 seconds to 11 
avoid tissue damage of the footpad.  For the tail flick test, the tail of mouse was 12 
immersed in water maintained at 52.5℃ and the time for the mouse to flick their tail 13 
was recorded as withdrawal latency. The maximum time of heat stimulus was 30 14 
seconds to avoid tissue damage of the tail. 15 
 16 
Formalin test 17 
A volume of 20 µl of 1% formalin solution was injected through a fine-gauge 18 
needle subcutaneously into the dorsal surface of one hind paw.  The length time 19 
engaged in licking and biting of the hind paw was recorded in the first 10 minutes and 20 
then between the 20 minutes to 30 minutes time points.  The first 10 minutes or 21 
Phase I measured the acute pain response to the chemical.  The period between 20 to 22 
30 minutes is the Phase II pain response to inflammation.  23 
 24 
Abdominal constriction tests 25 
Mice were injected intraperitoneally with 10 ml/kg of 0.6% acetic acid or 10 26 
 7 
ml/kg of 12 mg/ml Magnesium sulfate as control.  They were then placed in an 1 
observation cage and the numbers of abdominal constrictions within the first 5 2 
minutes or within 30 minutes were recorded.  3 
 4 
Open field test 5 
Mice were placed in a 240 x 240 mm transparent plastic box for assessment.  A 6 
100x100 mm arena at the center of the box was marked.  The movement was 7 
recorded by a video camera that was connected to a computer for tracking and 8 
recording.  The data were analyzed with EthoVision (Noldus) software, which 9 
revealed the total time the mouse was in motion, total distance traveled, velocity, and 10 
time spent in the center arena or margin of the arena. 11 
 12 
Porsolt swim test 13 
The cylinder with 100 mm diameter was filled with water to at least 100 mm 14 
height.  Day 1 was a training session.  Mice were placed in water-filled cylinder for 15 
6 minutes.  Testing sessions were performed on Day 2.  Mice were placed in a 16 
water-filled cylinder for 6 minutes, and its movement was recorded by a video camera 17 
and analyzed by EthoVision (Noldus) software as above. 18 
 19 
Measurement of nerve conduction velocity  20 
The nerve conduction velocity was measured in mice with 9 to 11 week-old according 21 
to the protocol mentioned previously [20,21].  Briefly, mice were anesthetized with 22 
Ketamine (100 mg/kg)/ Xylazine (10 mg/kg) and the sciatic nerve were stimulated 23 
(5-10 V, 0.05 ms single square-wave pulses) proximally with platinum needle 24 
electrodes (Grass, Quincy, MA).  Compound muscle action potentials were recorded 25 
from the ipsilateral foot between digit 2 and 3.  Afterwards, the length of sciatic 26 
 8 
nerve was measured.  The first compound action potential from individual 1 
stimulation was used for the measurement of motor latency, while the second one was 2 
used for the measurement of sensory latency.  NCV was calculated by difference of 3 
latencies between stimulation sites (Latency of M-wave (Notch) - Latency of M-wave 4 
(Ankle)) over the length of sciatic nerve [22]. 5 
 6 
Protein analysis using Western blotting 7 
Lumbar 4 to 5 spinal cords were dissected from mice 5 minutes, 30 minutes or 1 day 8 
post-formalin injection into their footpads.  Spinal cords were rinsed with ice-cold 9 
PBS and separated longitudinally through the anterior median fissure to the posterior 10 
median sulcus.  The half of spinal cord, which received the injection of PBS or 11 
formalin, was defined as the ipsilateral side, whereas the uninjected side was defined 12 
as contralateral side.  Each half of spinal cord was lysed separately by sonication in 13 
lysis buffer (50 mM Tris HCl pH7.4; 1% NP-40; 0.25% Na-deoxycholate; 150 mM 14 
NaCl; 1 mM PMSF) and 50µg of protein extract was subjected to 12% 15 
SDS-polyacrylamide gel electrophoresis (PAGE).  The gel was transferred to a 16 
polyvinylidene difluoride membrane (Hybond-P, GE healthcare).  The membrane 17 
was blotted with anti-pERK (1:1000, cell signaling), and then rescreened with 18 
anti-total ERK (1:1000, cell signaling) and then finally blotted with anti-GAPDH 19 
(1:1000, abcam).  The immunoreactivity was detected with enhanced 20 
chemiluminescence according to the procedure provide by GE healthcare. 21 
 22 
Rhotekin binding assay 23 
Tissues were lysed by sonication in lysis buffer (50 mM Tris HCl pH7.4; 1% NP-40; 24 
0.25% Na-deoxycholate; 150 mM NaCl; 1 mM PMSF).  Each sample was sonicated 25 
twice for 30 seconds.  The lysates were spun at 13,000 rpm for 2 minutes at 4oC.  26 
 9 
The amount of protein was measured by BioRad protein assay.  The lysates were 1 
diluted into 1µg/µl.  500 µl of diluted lysates were used for RhoA-pull down assay.  2 
10 µl of cleaned agarose beads (Glutathione Sepharose 4B, GE Healthcare) were 3 
added to each sample and incubated for 1 hour at 4oC.  The lysates were transfer to 4 
new tubes and 50 µg of GST-RBD (GST fusion protein containing RhoA-binding 5 
domain of Rhotekin) bead was added into each sample and incubated with shaking for 6 
1 hour at 4oC.  The supernatant was removed and the beads were washed in washing 7 
buffer for three times.  Bound proteins were fractionated on 12% SDS/PAGE and 8 
detected with polyclonal antibody for RhoA (1:1000, Santa Cruz Biotechnology).  9 
Total tissue lysate was also analyzed with anti-RhoA antibody as a loading control.  10 
The level of active RhoA was determined after normalization with the total RhoA 11 
present in the tissue lysates. 12 
 13 
In vivo quantification of cutaneous nerve in live animals 14 
The method of quantification of cutaneous nerves was according to the protocol 15 
mentioned previously [23]. Briefly, animals were anesthetized with Ketamine 16 
(100mg/kg)/ Xylazone (10mg/kg).  Hair on a defined area of the leg was removed 17 
and cleaned by PBS.  Three squares of 4mm x 4mm were marked on both legs: 18 
mid-calf, mid-thigh and one in between those two areas.  The YFP positive small 19 
cutaneous fibers were quantitated under fluorescence stereomicroscope.  The density 20 
of all primary and secondary YFP positive nerve fibers in these areas of the legs was 21 
expressed as average number of YFP positive fiber per 100mm2 (# fibers/100mm).  22 
The observer was blinded to the genotype of experimental animals.  The image of 23 
YFP positive nerve fibers were captured by the Leica DC500 camera attached to the 24 
fluorescence stereomicroscope and processed with Leica IM 50 software. 25 
 26 
 10 
Histological and Immunocytochemical analysis 1 
Footpad skins of mice were harvested and embedded in OCT.  The skin samples 2 
were sectioned at 60 µm and were mounted on poly-L-lysine coated glass slide, and 3 
then the sections were dried on the drier at 37 oC for 30 minutes.  The sections were 4 
washed with 1xPBS for 5minutes and post-fixed with 4% PFA for 5minutes.  After 5 
fixation, the sections were rinsed with 1xPBS for 5minutes.  The slides were 6 
mounted with FluorSaveTM (Merck Ltd.) and coverslip.  Five regions of skin section 7 
were chosen and the images of these five regions were taken by using Confocol 8 
microscope (Zeiss 510-Meta).  The criteria of counting small free ending nerve was 9 
followed the methods describe in Lauria et al [24] 10 
 11 
Lumbar 4 to 5 spinal cords were dissected from mice 5 minutes, 30 minutes or 1 day 12 
after they received the 1% formalin injection into their footpads.  The spinal cords 13 
were fixed in 4% paraformaldehyde for 2 hours at room temperature (RT) and then 14 
perfused with 20% sucrose overnight at 4 oC.  The cryopreserved spinal cords were 15 
sectioned at 20 µm using cryostat (CM3000, Leica) and then mounted on 16 
poly-L-lysine coated glass slides.  17 
 18 
Spinal cord sections were submerged in 4% paraformaldehyde (PFA) for 20 minutes 19 
at RT and then washed 3 times in phosphate-buffered saline (PBS) for 5 minutes.  20 
Diluted primary antibodies (anti-phosphorylated ERK1/2 (1:100, Cell signaling) was 21 
applied and incubated at 4oC for 16-18 hours The sections were then washed 3 times 22 
with 1xPBS for 5 minutes.  For pERK staining, diluted secondary antibodies (goat 23 
anti-rabbit) were applied to each section and were incubated at room temperature in 24 
the dark for 60 minutes.  After secondary antibody incubation, slides were washed 25 
with 1x PBS for 5 minutes.  The ABC complex was added to each section and 26 
 11 
incubated for 30 minutes at RT. Slides were then washed with 1x PBS for 5 minutes.  1 
The sections were then incubated in daminobenzidine (DAB) for 2 minutes and then 2 
rinsed in 1x PBS.  After washing off the antibody, images were captured using 3 
fluorescent microscope (Leica).  The numbers of pERK-positive neurons in the 4 
superficial laminae (I–II) quantitated according to the method of mentioned in 5 
previous reports [25,26]. 6 
 7 
Morphometric analysis of sural nerves  8 
Sural nerves of DLC2+/+ and DLC2-/- mice were harvested and were fixed in primary 9 
fixative overnight at 4 oC.  Then, the tissues were rinsed in 0.1 M phosphate buffer 3 10 
times for 5 minutes.  The tissues were post-fixed in 1% Osmium tetroxide for 2 11 
hours at 4 oC.  After post-fixation, the tissues were rinsed in 0.1 M phosphate buffer 12 
3 times for 5 minutes.  After washing, the tissues were dehydrated in ascending 13 
ethanol series.  After dehydration, tissues were infiltrated with propylene oxide, and 14 
propylene oxide: Epon (50:50) for 1 hour.  Tissues were transferred to 100% Epon 15 
for overnight on rotator, embedded in epon and polymerized in 60 oC oven for 72 16 
hours.  The 1 µm thick transverse sections of nerves were cut using Ultracut 17 
(Reichert-Jung, Leica) mounted on TESPA coated glass slides and counter-stained 18 
with toludine blue.  The photomicrographs of sural nerves were taken at a 19 
magnification of 1,000X using a computer-assisted image analyzing system (SPOT).  20 
Fascicular area, feret diameter, myelinated fiber number and size were analysed and 21 
measured by ImageJ (NIH).  22 
 23 
Statistical analysis 24 
All data were expressed as means ± SEM. Statistical analysis was performed by 25 
 12 
Student t-test, Mann Whitney or One-way ANOVA.  P values 0.05 were considered 1 
statistically significant. 2 
 3 
Results 4 
DLC2 mRNA is expressed in brain, spinal cord and sciatic nerve tissue   5 
To analyze the role of DLC2 in the neural control of pain, gene expression in 6 
brain, spinal cord and peripheral nerve tissue was analyzed using semi-quantitative 7 
RT-PCR.  As shown in Figure 1 A, DLC2 mRNA was present in each tissue and as 8 
expected, absent in the corresponding tissues from DLC2-/- mice.  Within the brain, 9 
DLC2 expression was high in the cortex, cerebellum, hippocampus, and brainstem 10 
and low in the midbrain and olfactory bulb.  In situ hybridization confirmed that 11 
DLC2 mRNA is localized in neurons of DLC2+/+ mice in the above-mentioned 12 
regions, and expression was not detected in these areas in DLC2-/- mice.  (Fig. 1 B). 13 
 14 
Increased RhoA activity in nervous tissues of DLC2-deficient mice 15 
The role of DLC2 as a RhoGAP specific for RhoA was established using cell 16 
lines [11,27].  However, this function has not been confirmed in animal tissues.  17 
Therefore, RhoA activity in the brain and the peripheral nerves of DLC2+/+ and 18 
DLC2-/- mice was assessed using the Rhotekin binding assay [11,27]. Significant 19 
differences in RhoA activity were not found in the brain tissue of DLC2+/+ and 20 
DLC2-/- mice (N=5) (Fig. 1 C-ii).  Interestingly, RhoA activity was significantly 21 
increased in the peripheral nerves of DLC2-/- mice compared to that of DLC2+/+ mice 22 
(Fig. 1 C-iv).  23 
 24 
DLC2-deficient mice experience more severe hyperalgesia  25 
Because RhoA has been implicated in pain sensation, and the regions of the brain 26 
 13 
in which DLC2 was highly expressed have been linked to pain processing pathways 1 
[28-32], we determined whether DLC2 is involved in pain sensation.  We compared 2 
the response of 9-11-week-old DLC2+/+ and DLC2-/- mice to noxious thermal stimuli 3 
and inflammatory chemical-induced pain.  In the hot plate and tail flick tests, 4 
DLC2-deficient mice showed shorter paw and tail withdrawal latencies than the 5 
DLC2+/+ mice, suggesting that the former were more sensitive to painful thermal 6 
stimuli (Fig. 2 a, b).   7 
 8 
An injection of 1% formalin to the right hind paw causes the mouse to lick, bite 9 
its paw, and flinch its leg.  Such behavioral responses occur within 10 minutes 10 
(Phase I) and within 20-30 minutes (Phase II) of the formalin injection.  Phase I is 11 
also referred to as the acute phase, whereas the Phase II is often referred to as 12 
inflammation-induced pain phase.  During Phase I, the frequency of licking and 13 
flinching of DLC2-/- mice was not different from that of DLC2+/+ mice.  However, 14 
DLC2-/- mice showed a significantly more intense Phase II pain response than the 15 
DLC2+/+ mice.  These mice spent more time biting, licking or flinching their right 16 
hind paw (Fig. 2 d).  The enhanced response to inflammatory pain in the 17 
formalin-injected DLC2-/- mice was not due to more severe inflammation, as both 18 
DLC2-/- and DLC2+/+ mice showed a similar degree of swelling in the right hindpaw 19 
(data not shown).  20 
 21 
 An intraperitoneal injection of acetic acid and magnesium sulfate produces 22 
acute inflammatory pain and acute non-inflammatory, prostaglandin-independent pain, 23 
respectively [33].  In response to the acetic acid injection, DLC2-/- mice showed 24 
significantly more abdominal constriction than DLC2+/+ mice (Fig. 2 e).  In contrast, 25 
injection of magnesium sulfate resulted in a similar response in the DLC2-/- and 26 
 14 
DLC2+/+ mice (Fig. 2 f).  1 
 2 
DLC2-deficient mice have normal locomotor activity and do not exhibit anxiety 3 
or depressive behaviors  4 
DLC2 expression was analyzed in the hippocampus and the zona incerta, which 5 
are involved in locomotor activity, anxiety, depressive-like behavior and pain 6 
modulation.  In addition, anxiety is one of the potential components of the pain 7 
response [34]. Therefore, we examined DLC2-/- mice to determine whether they have 8 
any abnormalities in locomotive function, anxiety or depressive behavior.  9 
 10 
In the open field test, which examines general exploratory and locomotor activity, 11 
no significant differences in the total duration of locomotor activity and total distance 12 
traveled within one hour were observed between DLC2-/- and DLC2+/+ mice,  13 
suggesting that the loss of DLC2 expression did not affect habituation (Fig. 2 g, h).  14 
In addition, no significant difference in the moving velocity was observed between the 15 
mice, suggesting that locomotor activity was not affected by the DLC2-deficiency 16 
(Fig. 2 i).  Furthermore, no differences in the time spent in the center of the test field 17 
were observed, suggesting that each genotype had a normal level of anxiety (Fig. 2 j).  18 
 19 
In the Porsolt swim test, which is designed to reveal depression-like behavior 20 
[33,35], DLC2-/- mice behaved similar to the DLC2+/+ mice in terms of the amount of 21 
struggling time and the amount of time spent floating (Fig. 2 k).  An increase in the 22 
floating time is indicative of depression because mice stop trying to get out of the 23 
water.  24 
 25 
DLC2-deficient mice show increased sensory nerve conduction velocity, but the 26 
 15 
sural nerve morphology appears normal  1 
Sensory (SNCV) and motor nerve conduction velocity (MNCV) in the sciatic 2 
nerve of 9-11-week-old DLC2+/+ and DLC2-/- mice was determined as described in the 3 
Materials and Methods.  The DLC2-/- mice MNCV appeared normal (Fig. 2 l); 4 
however, the SNCV was increased compared to that of the DLC2+/+ mice (Fig. 2 m).   5 
 6 
Because only the SNCV was affected in DLC2-/- mice, the sensory nerve 7 
morphology (i.e., sural nerve) of the DLC2+/+ and DLC2-/- mice was examined (Fig. 3 8 
a, b).  Semi-thin (1 µm) sections of the sural nerve were prepared, and morphometric 9 
analysis of the myelinated fibers was performed because these fibers are likely to 10 
affect nerve conduction velocity.  These data showed no difference in the fascicular 11 
area and minimum feret diameter (Fig. 3 c, d), the number and density of myelinated 12 
fibers (Fig. 3 e, f), axon diameter (Fig. 3 g, h), and thickness of myelin (Fig. 3 i) 13 
between DLC2-/- and DLC2+/+ mice.  In addition, the area of un-myelinated fibers 14 
was not significantly different between DLC2+/+ and DLC2-/- mice (Fig. 3 j).  Taken 15 
together, these data suggest that the loss of DLC2 does not affect sural nerve 16 
morphology. 17 
 18 
The number of cutaneous nerve fibers is not different between DLC2+/+ and 19 
DLC2-/- mice 20 
A transgene that labels nerve fibers with a yellowish-green fluorescent protein 21 
(YFP) [23] was introduced into DLC2+/+ and DLC2-/- mice to facilitate non-invasive 22 
visualization of cutaneous nerve fibers. Both small and large YFP-labeled fibers in the 23 
skin can be visualized under the fluorescent microscope (Fig. 3 k).  Large nerve 24 
fibers were found in the dermis parallel to the skin surface (red arrow, Fig. 3k-i).  25 
The small fibers (white arrowhead, Fig. 3 k-i) in the epidermal layer perpendicular to 26 
 16 
the skin surface were cutaneous nerves.  The nerves that branched out from the large 1 
fibers were termed primary fibers (Fig. 3 k-ii, white arrowhead), whereas those 2 
bifurcating from the primary fibers (Fig. 3 k-iii, white arrow) were termed secondary 3 
fibers. Non-invasive microscopic visualization was unable to distinguish between 4 
myelinated and un-myelinated fibers.  5 
 6 
We quantified the cutaneous nerve fiber density in three regions of the thigh in 7 
9-11-week-old DLC2+/+ YFP and DLC2-/- YFP mice [23].  As shown in Figure 3 l, 8 
there was no significant difference in the primary and secondary cutaneous nerve 9 
fibers between DLC2+/+ and DLC2-/- mice.  The cutaneous nerve fiber density within 10 
the epidermis and perpendicular to the dermis in five regions of the footpad skin was 11 
also examined and also showed no difference between the DLC2+/+ and DLC2-/- mice 12 
(Fig. 3 m, n). 13 
 14 
RhoA activity in spinal cord of DLC2-deficient mice is increased 30 minutes after 15 
a formalin injection 16 
To determine whether RhoA was involved in the Phase II hyperalgesia response 17 
in DLC2-/- mice, RhoA activity in the spinal cord 30 minutes after the formalin 18 
injection was determined.  In DLC2+/+ mice, the RhoA activity was not different 19 
between the ipsilateral (same side as formalin injection) and contralateral (opposite 20 
side of formalin injection) side of the L1-S1 spinal cord (Fig. 4).  In DLC2-/- mice, a 21 
significant increase in RhoA activity was observed in the ipsilateral side of spinal cord 22 
compared to the contralateral side (Fig. 4 b).   23 
 24 
The number of phosphorylated ERK1/2-positive cells in spinal dorsal horn is 25 
increased 26 
 17 
Phosphorylation of ERK in the spinal dorsal horn is thought to play an important 1 
role in the inflammatory pain response [36].  To determine whether ERK1/2 is 2 
involved in hyperalgesia in DLC2-/- mice, spinal cords were dissected 5 minutes and 3 
30 minutes after a formalin injection and were stained with antibodies against 4 
phosphorylated ERK1/2 (pERK1/2).   5 
 6 
In naïve DLC2+/+ and DLC2-/- mice, the number of pERK1/2-positive cells in the 7 
superficial layer of spinal dorsal horn was not significantly different (Fig. 5a).  The 8 
number of pERK1/2-positive cells in the ipsilateral dorsal horn of DLC2+/+ mice was 9 
significantly increased 5 minutes after the injection in comparison to the contralateral 10 
side (Fig. 5 a-i and 5a-ii).  The number of pERK1/2-positive cells in the ipsilateral 11 
side of DLC2-/- mice was also significantly higher in comparison to the contralateral 12 
side (Fig. 5 a-iii and 5 a-iv); however, the degree of increase was much more than that 13 
of DLC2+/+ mice (Fig. 5 a-i, a-iii and Fig. 5 d-i).  At 30 minutes after the formalin 14 
injection, the number of pERK1/2-positive cells in the superficial spinal dorsal horn 15 
was reduced in both the contralateral and ipsilateral sides in the DLC2+/+ and DLC2-/- 16 
mice (Fig. 5 c and d-ii), and no significant difference in the number of 17 
pERK1/2-positive cells was observed. 18 
 19 
Western blot analysis confirmed that the pERK1/2 level in the ipsilateral spinal 20 
cord of DLC2-/- mice was significantly higher than that of the DLC2+/+ mice (Fig. 5 21 
d-iii and d-iv).  However, the difference in pERK1/2 expression between the 22 
contralateral and ipsilateral spinal cord of the DLC2+/+ and the difference of pERK1/2 23 
expression between the contralateral and ipsilateral spinal cord of DLC2-/- mice was 24 
not observed in the quantitative Western blot histogram.  25 
 26 
 18 
Discussion 1 
 2 
Loss of DLC2 does not affect locomotor activity, anxiety and depression  3 
In this report, we showed that DLC2 null mice were more sensitive to noxious 4 
thermal stimuli and chemically induced inflammatory pain.  DLC2 is a newly 5 
identified RhoGAP specific for RhoA [1,11].  Several RhoGAPs are thought to be 6 
involved in neuronal morphogenesis.  Oligophrenin-1 appears to play a role in 7 
neurite outgrowth and the regulation of synaptic connectivity [37].  p250GAP, which 8 
is a RhoGAP for RhoA and Cdc42, is enriched in the NMDA receptor complex and 9 
regulates dendritic spine structure in an NMDA receptor-dependent manner [38].  10 
DLC1 is also a RhoGAP specific for RhoA and Cdc42 [39], and it is thought to be 11 
involved in neural tube development.  DLC1 null mice die in utero due to defects in 12 
neural tube development [40].  One of the RhoGAPs, p190GAP, is involved in axon 13 
guidance and fasciculation [41].  Interestingly, DLC2 null mice appeared normal 14 
with no obvious abnormality in the nervous tissues.  Their locomotor activity 15 
appeared normal without exhibiting any signs of anxiety-like or depression-like 16 
behavior in the open field test and Porsolt swim test, respectively.  The morphology 17 
of the cutaneous nerves, such as the sural nerve, appeared normal.  18 
 19 
More severe hyperalgesia is observed in DLC2-deficient mice 20 
Interestingly, DLC2-/- mice were more sensitive to noxious thermal stimuli and 21 
inflammatory pain.  An hyperalgesic response to noxious thermal stimuli was 22 
observed in the hot plate and tail flick tests.  In addition, an hyperalgesic response to 23 
inflammatory pain was determined by quantifying the Phase II response during a 24 
formalin test.  The abdominal constriction response to an inflammatory agent was 25 
also determined.  DLC2-/- mice were hypersensitive to acetic acid-induced 26 
 19 
(inflammatory) pain, whereas they exhibited a normal response to magnesium 1 
sulfate-induced (non-inflammatory acute) pain.  Hyperalgesia to inflammatory pain 2 
in DLC2-/- mice was not due to increased inflammation in the injected footpads, as the 3 
swelling of the injected footpads was not significantly different from that of the 4 
DLC2+/+ mice (data not shown).  Taken together, these observations indicate that 5 
DLC2 is involved in the modulation of pain sensation.  DLC2 expression was 6 
present in several regions of the brain that are involved in pain modulation, including 7 
the hippocampus CA1 region [31], dentate gyrus [42] and zona incerta [43].  8 
 9 
SNCV is increased in DLC2-/- mice 10 
The DLC2-/- mice showed a normal MNCV, although the SNCV was increased 11 
compared to that of the DLC2+/+ mice.  The SNCV measured in this study was the 12 
conduction velocity of a H-reflex, which runs from the sensory nerves to the spinal 13 
cord and back to the motor nerves [44].  A faster SNCV may thus contribute to a 14 
shorter withdrawal latency in the hot plate test and the tail flick test.  Increased 15 
RhoA activity in the peripheral nerves of DLC2-/- mice may also contribute to the 16 
hypersensitivity to thermal stimuli, as the activation of RhoA and ROCK induce 17 
neurotransmitter release through a reorganization of the actin cytoskeleton [14].  18 
 19 
The increased SNCV in DLC2-/- mice was not associated with a noticeable 20 
change in the structure of the sural nerves.  The fascicular area, the number of 21 
myelinated fibers and axon diameter were similar in both the DLC2+/+ and DLC2-/- 22 
mice.  Unfortunately, the resolution of the sural nerve semi-thin sections was not 23 
sufficient to reveal the morphology of the un-myelinated fibers.  The area of 24 
un-myelinated fibers in the sural nerves was determined by deducing the fascicular 25 
area by the area of the myelinated fibers.  The area of the un-myelinated fibers in the 26 
 20 
sural sections was not significantly different between DLC2+/+ and DLC2-/- mice.  1 
Our data suggest that DLC2-/- mice have normal sural nerve morphology and 2 
myelination.   3 
 4 
In addition to the nerve structure, the post-synaptic release of nitrite oxide (NO) 5 
and its subsequent diffusion play an important role in synaptic plasticity and 6 
long-term potentiation [45]. ROCK regulates NO release through the stimulation of 7 
prostaglandin E2 (PGE2) [46].  Determining NADPH-diaphorase and nNOS activity 8 
in the DLC2-/- mice would shed light on the role of RhoA in nerve conduction 9 
velocity.  Moreover, RhoA activation induces the release of neurotransmitters such 10 
as glutamate through the reorganization of the actin cytoskeleton at the cell periphery 11 
by activating ROCK and myristoylated alanine-rich C-kinase substrate (MARCKS) 12 
[17].  The increase in pre-synaptic RhoA activity also induced acetylcholine release 13 
in C. elegans through an unknown mechanism [18].  Therefore, increased SNCV in 14 
DLC2-/- mice may be the result of altered synaptic connectivity and function, although 15 
further studies are required to support this hypothesis. 16 
 17 
RhoA activity is increased in the spinal cord of DLC2-/- mice after a formalin 18 
injection 19 
The injection of formalin into the rodent hindpaw produces two distinct phases 20 
of nociceptive behavior.  These two pain phases involve different physiological 21 
mechanisms.  The Phase I pain response occurs during the chemical activation of 22 
primary afferent nociceptors at the injection sites, whereas the Phase II pain response 23 
is the result of factors released from local inflammation at the injection site.  In this 24 
study, the DLC2-/- mice displayed a hyperalgesic Phase II response after the formalin 25 
injection, indicating that DLC2 may modulate inflammatory pain.  This phenotype 26 
 21 
was confirmed by the acetic acid abdominal contraction test (Fig. 2e), which is 1 
another inflammatory pain test.  2 
 3 
Hyperalgesia induced by inflammatory pain in DLC2-/- mice may involve RhoA.  4 
A dramatic increase in RhoA activity was observed in the ipsilateral spinal cord 30 5 
minutes after the formalin injection.  It is well known that the activation of RhoA 6 
and its effector, ROCK, is related to spinal nociceptive transmission [14,47-49] and 7 
that the inhibition of ROCK attenuates inflammatory and neuropathic pain [13,47].  8 
In addition, a recent paper showed that the RhoA/ROCK pathway is also involved in 9 
thermal hyperalgesia in diabetic mice [50].  Furthermore, the activation of RhoA and 10 
ROCK is related to spinal nociceptive transmission [14,47-49], and the inhibition of 11 
ROCK attenuates inflammatory and neuropathic pain [13,47], whereas the activation 12 
of RhoA by the injection of LPA induces hyperalgesia and allodynia [13].  The 13 
injection of H-1152, a ROCK inhibitor, significantly reduced the Phase II pain 14 
behavior resulting from a formalin injection by attenuating the phosphorylation of 15 
MARCKS in the superficial dorsal horn of the spinal cord [14].  Therefore, RhoA 16 
and ROCK are important regulators of inflammatory pain, and the de-regulation of 17 
RhoA may influence the inflammatory pain response. 18 
 19 
The in vivo function of the DLC2-RhoGAP domain has not been fully 20 
determined.  In vitro, the DLC2-RhoGAP domain showed Rho-GAP activity for 21 
RhoA and CDC42 [1], and the over-expression of DLC2 inhibited RhoA activity, 22 
resulting in the reduction of actin stress fiber formation [11,51] and suggesting that 23 
DLC2 predominately regulates RhoA.  Because DLC2 is a negative regulator of 24 
RhoA, it may be involved in the suppression of RhoA activity.  These data suggest 25 
the activity of RhoA may be negatively regulated by DLC2 in pain modulation.   26 
 22 
 1 
ERK1/2 signaling may affect DLC2-induced hyperalgesia 2 
ERK1/2 activation is involved in the inflammatory pain response but does not 3 
affect basal pain sensitivity [26].  Increased ERK1/2 activation was detected after 4 
Complete Freund's Adjuvant (CFA)-induced inflammatory pain [26].  In addition, 5 
the inhibition of pERK1/2 attenuates inflammatory [25,36,52], heat and mechanical 6 
pain hypersensitivity [26].  In this study, we observed an increase in the number of 7 
pERK1/2-positive cells in the ipsilateral dorsal horn of the spinal cord (L4 and L5) of 8 
DLC2-/- mice 5 minutes after a formalin injection, which is similar to a previous 9 
report [25].  The activity of ERK1/2 in both sides of the spinal cord was increased in 10 
DLC2-/- mice compared to DLC2+/+ mice.   11 
 12 
In contrast to the immunocytochemical data, the quantitative Western blot 13 
analysis did not show an increase in pERK1/2 in the ipsilateral spinal cord compared 14 
to the contralateral side in the DLC2+/+ mice 5 minutes after a formalin 15 
injection.  Western blot analysis showed that pERK1/2 was increased in both the 16 
contralateral and ipsilateral sides of the spinal cord in DLC2-/- mice compared to 17 
DLC2+/+ mice 5 minutes after a formalin injection.  Nevertheless, an increase in 18 
pERK1/2 in the ipsilateral dorsal horn of the spinal cord in DLC2-/- mice was 19 
observed compared to DLC2+/+ mice 5 minutes after a formalin injection.   20 
 21 
The activation of ERK1/2 peaks 5 minutes after stimulation and then decays 30 22 
to 60 minutes after stimulation [25,26,53].  It is not yet clear whether ERK1/2 23 
activation occurs 5 minutes after a formalin injection, but the hyperalgesic effects 24 
were observed during Phase II, 20-30 minutes post injection.  Some studies suggest 25 
that ERK1/2 is involved in the central sensitization to acute noxious stimuli [26] and 26 
 23 
increased excitability of spinal neurons through the phosphorylation of the A-type 1 
potassium channel, Kv4.2 [54].  In addition, ERK1/2 induces transcriptional changes 2 
in the spinal cord. pERK1/2 translocates to the nucleus and phosphorylates the 3 
transcription factor cAMP element-binding protein (CREB) and induces transcription 4 
via CREB kinase [55-57].  Moreover, the activation of ERK has been shown to 5 
induce NK1, which plays an important role in inflammatory pain hypersensitivity 6 
[58,59], and the expression of prodynorphin, which is involved in 7 
inflammation-induced enhanced excitability and expanded dorsal horn neuronal 8 
receptive fields [60,61] after the induction of inflammatory pain [26].  Therefore, the 9 
activation of ERK may contribute to acute inflammatory hyperalgesia through post- 10 
translational and -transcriptional regulation.      11 
 12 
Recently, increasing evidences have suggested that RhoA regulates ERK1/2 13 
signaling directly or through the regulation of MEK [62-64], although evidence for a 14 
direct link between RhoA and ERK1/2 activation in nervous tissues has not yet been 15 
determined.  In this study, ERK1/2 activity in the ipsilateral spinal cord of DLC2-/- 16 
mice peaked 5 minutes after the formalin injection, whereas RhoA in the ipsilateral 17 
spinal cord of DLC2-/- mice was significantly activated 30 minutes post injection, 18 
after Phase II.  These data suggest that the induction of pERK1/2 in DLC2-/- mice 19 
during inflammatory pain may be independent of RhoA activation.  Whereas, a 20 
recent study showed that DLC2 up-regulated pERK1/2 in HepG2 through 21 
Raf-1-ERK1/2-p70S6K pathway [27], suggesting that further investigation is 22 
necessary to reveal the underlying mechanism involving DLC2, RhoA and ERK1/2 in 23 
pain perception.  24 
 25 
Taken together, we have shown that DLC2 has RhoGAP activity for RhoA in 26 
 24 
nervous tissue.  Loss of DLC2 led to the activation of RhoA and hyperalgesia after 1 
painful stimuli, such as formalin injection.  Concomitantly, increased ERK1/2 2 
phosphorylation was also observed in the ipsilateral side of spinal cord of DLC2-/- 3 
mice after injecting the animals with the inflammatory agent formalin (Fig. 6).  The 4 
ERK activation also induced hypersensitivity to pain through the up-regulation of 5 
various downstream effectors and an increase in neuronal excitability in the spinal 6 
cord [54].  Furthermore, ROCK activation downstream of RhoA may also contribute 7 
to hypersensitivity to pain by the phosphorylation of MARCKS and increased 8 
glutamate release.  However, the precise mechanism involving DLC2, RhoA and 9 
ERK1/2 has not yet been identified.  Therefore, further investigation is necessary to 10 
determine the detailed mechanism of DLC2 involvement in inflammatory pain.  11 
12 
 25 
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Legends for figures: 1 
 2 
Figure 1.  Disruption of the DLC2 gene result in a loss of DLC2 mRNA 3 
expression determined by semi-quantitative RT-PCR and visualized by in-situ 4 
hybridization:  A. Semi-quantitative RT-PCR showed the expression of DLC2 in 5 
brain, spinal cord and sciatic nerves in brain (i), sciatic nerve (ii) and spinal cord (iii) 6 
of DLC2+/+ mice and was absent in DLC2-/- mice.  Photomicrographs showed DLC2 7 
mRNA in various brain regions (N=3) (iv) and it was absent in all region of brain of 8 
DLC2-/- mice.  The expression of DLC2 mRNA was normalized with GAPDH.  Cx, 9 
Cortex; Ce, Cerebellum; Hi, Hippocampus; M, Middle part of brain; O, Olfactory 10 
bulb; Bs, Brainstem.  Data are showed as mean ± S.E.M.  B. Photomicrographs 11 
showed DLC2 mRNA expression in whole brain of DLC2+/+ (a) and was absent in 12 
brain of DLC2-/- mice (b).  (Scale bar: 1mm).  High magnification 13 
photomicrographs showed DLC2 mRNA expression in brain of mice in region of 14 
hippocampus (DLC2+/+ : c,d and DLC2-/- : e,f) and thalamus (DLC2+/+ : g,h and 15 
DLC2-/- : i,j) (Scale bar: 10µm).  CA1, field CA1 hippocampus; CA2, field CA2 16 
hippocampus; CA3, field CA3 hippocampuses; DG, dentate gyrus; CP, choroids 17 
plexus; DLG, dorsal lateral geniculate nuclei; PGMC, pre-geniculate nuclei 18 
magnocel ; SubG, subgeniculate nuclei ; ZIV, zona incerta ventral.  19 
Photomicrographs showed mRNA localization in DRG of DLC2+/+ (k) and DLC2-/- 20 
mice (l).  (Scale bar: 10µm).  C. Micrographs showed Western blotting of RhoA 21 
pull-down assay from brain (i) and peripheral nerves (including brachial plexus and 22 
sciatic nerves) (ii) of DLC2+/+ and DLC2-/- mice.  Upper band showed RhoA level 23 
after pulling down (Rho-GTP) and lower band showing total RhoA in protein extract.  24 
Histogram showed the quantification of active RhoA in brain (iii) and peripheral 25 
nerves (iv) of DLC2+/+ and DLC2-/- mice which was normalized by total RhoA in the 26 
extract (N=5).  Data are showed as mean ± S.E.M. * <0.05 by Mann-Whitney test.  27 
Y-axis represented ratio of RhoA-GTP/Total RhoA.  28 
 29 
Figure 2.  Pain perception tests in DLC2+/+ and DLC2-/- mice: 30 
(a) Histogram showing hotplate test in DLC2+/+ and DLC2-/- mice of 9-11 weeks old 31 
(N=15).  (b) Histogram showing Tail flick test in DLC2+/+ and DLC2-/- mice (N=13).  32 
(c) Histogram showing formalin-induced pain response in acute pain phase, which is 33 
10 minutes after injection.  (d) Histogram showing formalin induced pain response 34 
in inflammatory pain phase, which is the 20th to 30th minute after injection.  PBS 35 
control (N=3) group; experimental group (N=10).  (e) Scatter plot showing the 36 
number of abdominal constrictions within 30 minutes after injection of 0.6% acetic 37 
acid i.p, DLC2+/+ mice (N=9) and DLC2-/- mice (N=11).  (f) Scatter plot showing the 38 
 32 
number of abdominal constrictions within 5 minutes after injection of 120mg/kg 1 
MgSO4, (N=14).  (g) Graph showed the time spent in traveling in DLC2+/+ and 2 
DLC2-/- mice of 9-11 weeks old in open field test (N=7).  (h) Histograms showing 3 
the total time spent in traveling during 60 minutes in 9-11 weeks old mice (N=7).  (i) 4 
Histograms showed velocity of mice during 60 minutes in 9-11 weeks old mice (N=7).  5 
(j) Histograms showed the total time spent in central arena in open field test in 9-11 6 
weeks old mice (N=7).  (k) Histograms showed time spent in immobile in Porsolt 7 
swim test.  Histograms showing the motor (l) sensory (m) nerve conduction velocity 8 
in 9-11 weeks old of DLC2+/+ and DLC2-/- mice (N=10).  Data are showed as mean 9 
± S.E.M. * <0.05, **<0.01 by Mann-Whitney test.   10 
 11 
Figure 3.  Morphological study in nerves of DLC2-/- mice: Morphological 12 
analysis of sural nerve in DLC2+/+ and DLC2-/- mice: Semi-thin section of sural nerve 13 
of DLC2+/+ (a) and DLC2-/- (b) mice (Scale bar: 10µm) were stained with toludine 14 
blue.  (c) Histogram showing mean of fascicular area of sural nerve.  (d) Histogram 15 
showing mean of fascicular diameter of sural nerve.  (e) Histogram showing mean of 16 
total number of myelinated fibers.  (f) Histogram showing mean of myelinated fiber 17 
density of sural nerve.  (g) Histogram showing diameter of myelinated fiber in sural 18 
nerve.  (h) Histogram showing area diameter of axon.  (i) Histogram showing 19 
thickness of myelin in myelinated fiber.  Y-axis represented thickness of myelin 20 
(µm).  (j) Histogram showing the area of unmyelinated fiber.  Data are showed as 21 
mean ± S.E.M. N=5 in each group of animals.  (k) Photomicrographs showing the 22 
cutaneous YFP fiber in the leg (i).  The insert on the right hand panel (ii,iii) showed 23 
the magnified image of boxed area (1,2)  The white arrow heads pointed to the 24 
primary small fiber, and the white arrows pointed to the secondary small fibers.  The 25 
red arrow pointed to large nerve fibers in the dermis parallel to skin surface.  (l) 26 
Histogram showing the cutaneous small fiber density of DLC2+/+ and DLC2 -/- mice.  27 
N=7 in each group of animals.  Each column is shown as mean ± SEM. (Scale bar: 28 
100µm).  (m) Photomicrographs showing the cutaneous YFP small fiber in the skin 29 
section of plantar surface of DLC2+/+ /Thy1.2-YFP (1) and DLC2-/- /Thy1.2-YFP (2) 30 
mice.  The white arrows pointed to the representative free ending cutaneous YFP 31 
small fiber.  (n) Histogram showing the cutaneous small fiber density of DLC2+/+ 32 
and DLC2-/- mice.  Data are shown as mean ± SEM.  N=7 in each group of animals.  33 
k.l.: keratin layer; ep.: epidermis, d.: dermis.  (Scale bar: 50µm). 34 
 35 
 36 
 37 
 38 
 33 
Figure 4.  RhoA activity assay in DLC2+/+ and DLC2-/- mice 30 minutes after 1 
formalin injection: (a) Photograph showing Western blotting result of RhoA activity.  2 
Upper panel showing the level of active RhoA (RhoA-GTP), middle panel showing 3 
the level of total RhoA in lysate and lower panel showing the level of GAPDH in total 4 
lysate.  Con.: contralateral side of spinal cord; Ips: ipsilateral side of spinal cord.  (b) 5 
Histogram showing quantification of RhoA activity after formalin injection.  The 6 
activity RhoA was normalized with total RhoA in lysate.  Sample size was 8 in each 7 
group.  Data expressed as mean ± S.E.M. *<0.05 by 1-way ANOVA. 8 
 9 
Figure 5.  Phosphorylated ERK immunoreactivity in superficial dorsal horn of 10 
spinal cord after 1% formalin injection: a-c.  Representative micrographs showed 11 
the superficial dorsal horn of spinal cord in DLC2+/+ (i, ii) and DLC2-/- (iii, iv) mice 12 
with pERK1/2 immunocytochemical staining in naïve condition (a), 5 minutes 13 
post-formalin injection (b) and 30 minutes post-formalin injection (c).  No obvious 14 
pERK1/2 stained cells found on the both side of superficial dorsal horn in DLC2+/+ 15 
(a-i and a-ii) and DLC2-/- (a-iii and a-iv) mice in naïve condition.  The number of 16 
pERK positive cells (indicated with arrow in magnified images of (b-i) and (b-iii)) 17 
was quantified in ipsilateral (b-i, b.iii; c-i, c.iii) and contralateral (b-ii, b-iv; c-ii, c-iv) 18 
side of dorsal horn spinal cord.  d. Histogram showing the quantitation of pERK 19 
positive cells in superficial dorsal horn 5 minutes (d-i) or 30 minutes (d-ii) after 1% 20 
formalin injection.  Sample size was 4 in each group.  (Scale bar: 100µm).  d.iii. 21 
Photomicrograph showing the Western blotting of pERK in spinal cord 5 minutes 22 
after formalin injection.  d-iv.  Histograms showing the ratio of pERK1/2 (both 23 
band of pERK1/2) to total ERK1/2.  Data were shown as mean ± S.E.M. *<0.05; 24 
**<0.01, ***<0.001 by One-way ANOVA; # <0.05 by Student’s t-test). 25 
 26 
Figure 6.  Schematic diagram of the possible role of DLC2 and its downstream 27 
effectors: DLC2 involves in the regulation of inflammatory pain perception via RhoA 28 
and its two possible downstream effectors, ROCK and ERK.  Dotted lines indicate 29 
the effects between components, but the nature of their interaction remains to be 30 
investigated.  31 
 32 
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